Dr. Manolo Bellotto, General Manager and President of Gain Therapeutics, shares his personal story. You can follow him on : Twitter : @ManoloBellotto LinkedIn : https://www.linkedin.com/in/manolobellotto/
We sat down and got a chance to speak with the General Manager and President of Gain Therapeutics, Dr. Manolo Bellotto. You can follow him
Gain Therapeutics will be providing an update on our lead compound in development for GBA-associated Parkinson’s disease, GT-02287 at the Jefferies Global Healthcare Conference. Recent
MJFF 2021 Conference: What is Gain Therapeutics Presenting at the MJFF 2021 Parkinson’s Disease Therapeutics Conference Webinar? This year due to the impact of the
Allosteric Binding Sites: One of the most prevalent issues in drug discovery and development is the difficulty to find novel drug targets. Majority of disease-causing
Gain Therapeutics’ SEE-Tx patented algorithm provides quantitative predictions of druggable binding hot spots based on changes in binding free energy (ΔG). No other company has
MJFF 2021 Conference: The Michael J. Fox. Foundation (MJFF) has held a Parkinson’s Therapeutics Conference annually every fall, starting from 2009. Due to the COVID-19
Gain Therapeutics’ physics-based screening platform is able to identify previously unknown binding pockets on well-validated protein targets by identifying cavities on the surface and in
On April 20th, 2021, Gain Therapeutics announced a multi-target drug discovery and development deal with Zentalis Pharmaceuticals to identify and address novel oncology targets. Gain
At Gain Therapeutics, we are uniquely positioned to capitalize on the AlphaFold project and
extend the scope of our existing technology.
Just last month, AlphaFold launched their Protein Structure Database, containing high-quality predicted structures of every protein in the human body.
For years, the neuroscience industry has been plagued by a high failure rate of drugs in the clinical stages.
“We were thrilled to complete our IPO in March on the Nasdaq Global Market Exchange,” stated Sal Calabrese, Chief Financial Officer of Gain.
Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted
BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 11, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing
©2022 Gain Therapeutics, Inc